Cover Image
市場調查報告書

雷葛氏症候群:開發平台分析

Lennox-Gastaut Syndrome - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 321924
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
雷葛氏症候群:開發平台分析 Lennox-Gastaut Syndrome - Pipeline Review, H2 2016
出版日期: 2016年12月14日 內容資訊: 英文 68 Pages
簡介

兒童癲癇症──雷葛氏症候群(LGS)的特徵是頻頻發生嚴重發作。原因有皮質形成異常、先天性感染症、腦中風、精神性外傷、出生時缺氧、腦炎及髓膜炎等中樞神經系統感染症,或是遺傳性障礙等。治療方法有使用抗癲癇藥和飲食療法,手術。

本報告提供雷葛氏症候群的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

雷葛氏症候群概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

開發中的產品:各企業

研究中的產品:各大學/研究機關

開發治療藥的企業

  • Eisai
  • GW Pharmaceuticals plc
  • INSYS Therapeutics, Inc.

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

最新的開發中產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8798IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lennox-Gastaut Syndrome - Pipeline Review, H2 2016, provides an overview of the Lennox-Gastaut Syndrome (Central Nervous System) pipeline landscape.

Lennox-Gastaut syndrome is a severe form of epilepsy that typically becomes apparent during infancy or early childhood. The most common types of seizures associated with Lennox-Gastaut syndrome are tonic and atonic seizures. Causes of Lennox-Gastaut syndrome include cortical dysplasia, congenital infections, stroke, trauma, perinatal hypoxia, infections of the central nervous system such as encephalitis or meningitis and a rare, genetic disorder called tuberous sclerosis. Treatment includes antiepileptic drugs, dietary therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lennox-Gastaut Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Lennox-Gastaut Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lennox-Gastaut Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Lennox-Gastaut Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Lennox-Gastaut Syndrome.

Lennox-Gastaut Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Lennox-Gastaut Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Lennox-Gastaut Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Lennox-Gastaut Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Lennox-Gastaut Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Lennox-Gastaut Syndrome (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Lennox-Gastaut Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Lennox-Gastaut Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lennox-Gastaut Syndrome Overview
  • Therapeutics Development
    • Pipeline Products for Lennox-Gastaut Syndrome - Overview
    • Pipeline Products for Lennox-Gastaut Syndrome - Comparative Analysis
  • Lennox-Gastaut Syndrome - Therapeutics under Development by Companies
  • Lennox-Gastaut Syndrome - Therapeutics under Investigation by Universities/Institutes
  • Lennox-Gastaut Syndrome - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Lennox-Gastaut Syndrome - Products under Development by Companies
  • Lennox-Gastaut Syndrome - Products under Investigation by Universities/Institutes
  • Lennox-Gastaut Syndrome - Companies Involved in Therapeutics Development
    • Eisai Co Ltd
    • GW Pharmaceuticals Plc
    • INSYS Therapeutics Inc
    • Zogenix Inc
  • Lennox-Gastaut Syndrome - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fenfluramine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NRP-2945 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • perampanel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Voltage Gated Sodium Channels for Lennox Gastaut Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Lennox-Gastaut Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • Nov 22, 2016: New Data on Zogenixs ZX008 for Lennox Gastaut Syndrome & Dravet Syndrome to be Presented at 70th Annual American Epilepsy Society Meeting
      • Oct 28, 2016: Eisai To Initiate Two Phase III Clinical Studies For Antiepileptic Drug Perampanel (Fycompa) in Pediatric Patients With Partial-Onset or Primary Generalized Tonic-Clonic Seizures And In Patients With Seizures Associated With Lennox-Gastaut Syndrome
      • Sep 26, 2016: GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
      • Jun 27, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
      • Feb 25, 2016: Edison Issues ADR Update on GW Pharmaceuticals
      • Dec 07, 2015: GW Pharmaceuticals Announces New Physician Reports of Epidiolex Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy
      • Jun 11, 2015: GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study of Epidiolex in Lennox-Gastaut Syndrome
      • May 11, 2015: GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex (CBD) in Lennox-Gastaut Syndrome
      • Apr 23, 2015: Insys Therapeutics Commences Dosing in Phase 1/2 Safety and Pharmacokinetic Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients
      • Jan 12, 2015: Insys Therapeutics To Initiate Phase III study For An Epileptic Drug
      • Jun 25, 2014: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Rare Form of Epilepsy, Lennox-Gastaut Syndrome
      • May 07, 2014: GW Pharmaceuticals Receives Investigational New Drug From FDA for Phase 2/3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome
      • Feb 28, 2014: GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex in the Treatment of Lennox-Gastaut Syndrome
      • Sep 25, 2006: FDA Approves New Epilepsy Indication For Lamictal
      • Jan 15, 2004: New Expanded Indication For Lamictal Offers Additional Treatment Options For Adults With Partial Seizures
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Lennox-Gastaut Syndrome, H2 2016
  • Number of Products under Development for Lennox-Gastaut Syndrome - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Lennox-Gastaut Syndrome - Pipeline by Eisai Co Ltd, H2 2016
  • Lennox-Gastaut Syndrome - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Lennox-Gastaut Syndrome - Pipeline by INSYS Therapeutics Inc, H2 2016
  • Lennox-Gastaut Syndrome - Pipeline by Zogenix Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016

List of Figures

  • Number of Products under Development for Lennox-Gastaut Syndrome, H2 2016
  • Number of Products under Development for Lennox-Gastaut Syndrome - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top